LivaNova: Q2 Earnings Insights

Shares of LivaNova LIVN were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share were down 121.43% year over year to ($0.15), which beat the estimate of ($0.30).

Revenue of $182,200,000 declined by 34.27% from the same period last year, which beat the estimate of $169,730,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $1.15 and $1.35.

The upcoming fiscal year's revenue expected to be between $900,000,000 and $1,008,000,000.

Conference Call Details

Date: Jul 29, 2020

Time: 07:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/rznzyc3n

Recent Stock Performance

52-week high: $87.45

52-week low: $33.40

Price action over last quarter: Up 4.69%

Company Profile

U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!